Logo of BIofidus AG

AAV Characterization

AAV Characterization

The development of cell and gene-based therapeutics like AAV (adeno-associated virus) vectors has gained significant importance in recent years. We provide a comprehensive list of analytical methods for an in-depth characterization of your AAV construct. Through a targeted analysis setup of long read next-generation sequencing (ONT), quantitative PCR (qPCR), transmission electron microscopy (TEM) and LC-MS/MS techniques, we will provide you detailed information about the genome integrity, capsid surface and empty/full ratio characteristics of your product.

Our routine experts in sequencing and capsid protein characterization will guide you through the variety of available methods and help you find the optimal analytical solution for your project.

In accordance with your needs, we adapt and, if required, qualify (according to ICH guidelines) our platform methods tailored to your product, its individual formulation matrix and your distinct analytical question.

Get in contact with us to quickly find the optimal setup for your analytical challenge and to speak directly from expert to expert

Our capabilities

Standalone and integral bioanalytical services

Tell us about your project

We‘ll advice you to define your assay needs

By sending the contact form you agree to our privacy policy.
*By submitting this form, you are consenting to receive emails from: Biofidus AG. You can revoke your consent at any time by using the unsubscribe link, found at the bottom of every email. Please see our privacy policy.

Technologies used

Our Expert Tobias Luttermann advices you on for all inquiries related to AAVs and gene based therapies.

Phone: +49(0)521 89 739 064
Mail: Tobias.Luttermann@Biofidus.com

Tobias Luttermann Director Genome & Vector Characterization Biofidus AG
WordPress Cookie Hinweis von Real Cookie Banner